Risk factors for cardiovascular events after successful renal transplantation

Transplantation

Volumn 85, Issue 2, 2008, Pages 209-216

  Vanrenterghem, Yves F C ^a,e   Claes, Kathleen ^a   Montagnino, Giuseppe ^b   Fieuws, Steffen ^a   Maes, Bart ^a   Villa, Margarita ^b,c   Ponticelli, Claudio ^b,d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d Istituto Scientifico   (Italy)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cardiovascular morbidity; Mortality; Renal transplantation

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEMATOCRIT; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PULSE PRESSURE; SEX RATIO; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS;

EID: 38949158094     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318160254f     Document Type: Article

References (53)

1. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339.
2. Schnuelle P, Lorenz D, Trede M, Van der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: Evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9: 2135.
3. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
4. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 365: 147.
5. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 321: S112.
7. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606.
8. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451.
9. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
10. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154.
11. Hörl WH, Riegel W, Wanner C, et al. Endocrine and metabolic abnormalities following kidney transplantation. Klin Wochenschr 1989; 67: 907.
12. United States Renal Data System. USRDS 1999 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999.
13. Cecka JM. The UNOS Scientific Renal Transplant Registry. Ten years of kidney transplants. In: Terasaki PI, Cecka JM, eds. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1998.
14. Kaplan B, Schold J, Meier-Kriesche H-U. Overview of large database analysis in renal transplantation. Am J Transplant 2003; 3: 1052.
15. SAS/STAT User's Guide. Version 8. Raleigh, NC: STATS Publishing; 2000.
16. Zezina L, Dimeny E, Vessby B, Fellstrom B. Serum levels of antibodies against oxidised LDL in kidney graft recipients. Am J Nephrol 2002; 22: 539.
17. Busch M, Franke S, Muller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66: 338.
18. Friedman AN, Rosenberg IH, Selhub J, et al. Hyperhomocysteinemia in renal transplant recipients. Am J Transplant 2002; 2: 308.
19. Bertoni E, Marcucci R, Zanazzi M, et al. Hyperhomocysteinemia in renal transplant patients: An independent factor of cardiovascular disease. J Nephrol 2001; 14: 36.
20. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002; 13: 1918.
21. Holdaas H, Fellström B, Jardine A, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomized, placebo-controlled trial. Lancet 2003; 361: 2024.
22. Cosio FG, Falkentrain MF, Pesavento TE, et al. Patient survival data after renal transplantation II The input of smoking. Clin Tranplant 1999; 13: 336.
23. Fellstrom B. Risk factors for and management of posttransplantation cardiovascular disease. BioDrugs 2001; 15: 261.
24. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
25. Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) study. Circulation 2004; 110: 3667.
26. Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257.
27. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998; 32: 560.
28. Fernandez-Fresnedo G, Escallada R, et al. Association between pulse pressure and cardiovascular disease in renal transplant patients. Am J Transplant 2005; 5: 394.
29. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: A significant independent risk factor for graft failure and patient death. Transplantation 2002; 73: 70.
30. Howard RJ, Thai VB, Patton PR, et al. Obesity does not portend a bad outcome for kidney transplant recipients. Transplantation 2002; 73: 53.
31. Cosio FG, Alamir A, Yim S, et al. Patient survival after renal transplantation I. The impact of dialysis pre-transplant. Kidney Int 1998; 53: 767.
32. Meier-Kriesche HU, Kaplan B. Waiting time as the strongest modifiable risk factor for renal transplant outcomes: A paired donor kidney analysis. Transplantation 2002; 74: 1377.
33. Pascual J, Quereda C, Zamora J, et al. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc 2005; 37: 3746.
34. Pascual J, van Hooff JP, Salmela K, et al . Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82: 55.
35. Opelz G, Dohler B, Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005; 5: 720.
36. Maes BD, Claes K, Coosemans W, et al. Cessation of steroids in stable renal transplant patients: The Leuven experience. In: Cecka JM, Terasaki PI, eds. Clincal Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 2002: 181.
37. Montagnino G, Tarantino A, Segoloni G, et al. Long-term results of a randomized study comparing three immunosuppressive schedules with cyclosporine in cadaveric kidney transplantation. J Am Soc Nephrol 2001; 12: 2163.
38. Bunnapradist S, Daswani A, Takemoto SK. Graft survival following living-donor renal transplantation: A comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Transplantation 2003; 76: 10.
39. Cherikh WS, Kauffman HM, Maghirang J, et al. A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation. Transplantation 2003; 76: 463.
40. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
41. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296.
42. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285.
43. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
44. Fellstrom B, Holdaas H, Jardine AG, et al. Assessment of Lescol in Renal Transplantation Study Investigators: Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation 2005; 79: 205.
45. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458.
46. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899.
47. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004; 65: 626.
48. Winkelmayer WC, Chandraker A, Brookhart MA, et al. Prospective study of anemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant 2006; 21: 3559.
49. Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients-Aprospective cohort study. Am J Transplant 2007; 7: 818.
50. Drücke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071.
51. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with Epoetin Alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085.
52. Van Der Veen WJ. Does it matter where I live in Western Europe? An analysis of regional mortality differentials in Belgium, Germany and the Netherlands. Eur J Popul 1994; 10: 319.
53. Schaubel DE, Jeffery JR, Mao Y, et al. Trends in mortality and graft failure for renal transplant patients. CMAJ 2002; 167: 137.